Strongbridge Biopharma plc

Strongbridge Biopharma — Investor Presentation (February 2020)

42 slides from Strongbridge Biopharma's investor presentation, Feb 25, 2020

  1. Slide 1: Strongbridge Biopharma plc February 2020

    Slide 1: Strongbridge Biopharma plc February 2020

    BIOPHARMA PLC STRONGBRIDGE FEBRUARY 2020

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    Forward-looking statements This document contains forward-looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statement

  3. Slide 3: Strongbridge Biopharma is a revenue-generating rare disease company

    Slide 3: Strongbridge Biopharma is a revenue-generating rare disease company

    Strongbridge Biopharma is a revenue-generating rare disease company RECORLEV® (levoketoconazole) VELDOREOTIDE modified-release Approved for the treatment of Primary Periodic Paralysis (PPP) Phase 3 asset for the treatment of Cushing’s syndrome (CS) Next-generation somatostatin (SST) analog 2019 reve

  4. Slide 4: Management team

    Slide 4: Management team

    Management team John Johnson Richard Kollender Robert Lutz Fred Cohen, MD Executive Chairman Chief Operating Officer Chief Financial Officer Chief Medical Officer Emily Doyle Scott Wilhoit Stephen Long Brian Conner Chief Commercial Officer Chief Legal Officer Chief Compliance Officer Chief Human Res

  5. Slide 5: RECORLEV (levoketoconazole)

    Slide 5: RECORLEV (levoketoconazole)

    5 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established. RECORLEV (levoketoconazole)

  6. Slide 6: Endogenous Cushing's syndrome (CS) overview

    Slide 6: Endogenous Cushing's syndrome (CS) overview

    Endogenous Cushing’s Underlying cause is chronic exposure to EXCESS SERUM CORTISOL due to any of several etiologies syndrome (CS) overview Affects the whole body Psychosis, impaired memory, sleep disturbance, depression, anxiety Heart attacks, stroke, high blood pressure, high cholesterol, vein clot

  7. Slide 7: CS treatment paradigm

    Slide 7: CS treatment paradigm

    Cushing’s syndrome and etiology established biochemically ACTH – Dependent CS ACTH – Independent CS Not a candidate for surgery / ablation Unilateral or bilateral surgery / ablation Transsphenoidal pituitary surgery Persistent or recurrent hypercortisolemia Persistent hypercortisolemia Endocrine rem

  8. Slide 8: Levoketoconazole appears to be the relevant enantiomer of ketoconazole

    Slide 8: Levoketoconazole appears to be the relevant enantiomer of ketoconazole

    Levoketoconazole appears to be the relevant enantiomer of ketoconazole for cortisol synthesis inhibition in humans KETOCONAZOLE Racemate with Two Enantiomers DEXTROKETOCONAZOLE LEVOKETOCONAZOLE Right-handed enantiomer Left-handed enantiomer Estimated to contribute essentially no activity towards the

  9. Slide 9: Levoketoconazole is approximately twice as potent as ketoconazole

    Slide 9: Levoketoconazole is approximately twice as potent as ketoconazole

    Levoketoconazole is approximately twice as potent as ketoconazole for cortisol synthesis inhibition Progesterone Hydroxy esterone Cholesterol Pregnenolone 11-Deoxycortisol Cortisol 17-Hydroxy Pregnenolone CYP11A1 CYP17A1 CYP11B1 Ketoconazole, racemate 2,267 58 139 2.7x Dextroketoconazole 25,080 596

  10. Slide 10: SONICS Phase 3 study design

    Slide 10: SONICS Phase 3 study design

    SONICS, a successfully completed phase 3, multi-center, open-label, single-arm study Dose Titration 2 to 21 weeks Start at 150 mg 2x daily. Titrate in 150 mg increments up to 600 mg 2x daily as needed until mUFC** normalization or therapeutic dose otherwise established Maintenance 6 months Goal to m

  11. Slide 11: SONICS achieved statistical significance of the primary endpoint

    Slide 11: SONICS achieved statistical significance of the primary endpoint

    SONICS achieved statistical significance of the primary endpoint 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 Primary endpoint was achieved with statistical significance with 30% of patients (29/94) achieving mean urinary free cortisol (mUFC) normalization without a dose increase (95% CI:

  12. Slide 12: Sensitivity analyses support SONICS primary endpoint

    Slide 12: Sensitivity analyses support SONICS primary endpoint

    Sensitivity analyses of SONICS efficacy demonstration primary endpoint support Mean mUFC remained at approximately the upper limit of normal (ULN) from month 1 Sensitivity analyses mUFC ≥50% mUFC decrease or normalization at month 6 irrespective of dose increase through month 6 of maintenance (N=77)

  13. Slide 13: SONICS key secondary endpoints

    Slide 13: SONICS key secondary endpoints

    SONICS achieved statistical significance Mean Change from Baseline at end of Maintenance phase† (n) Adjusted* p-value of mean reductions from Baseline Baseline Mean (n) Outcome Measure in Fasting Blood Glucose Hemoglobin A1c Total cholesterol LDL-cholesterol Body Weight 5.8 mmol/L (76) 6.0% (77) 5.6

  14. Slide 14: Most commonly reported treatment emergent adverse events in SONICS

    Slide 14: Most commonly reported treatment emergent adverse events in SONICS

    Most commonly reported treatment emergent adverse events in SONICS Treatment Emergent Adverse Events Treatment Emergent Adverse Events of Special Interest (all phases combined) N=94 (all phases combined) Nausea 33% Headache 29% Liver-related 7% Hypertension 19% QTc prolongation 7% Peripheral edema 1

  15. Slide 15: Liver enzyme cross-study comparison

    Slide 15: Liver enzyme cross-study comparison

    Liver enzyme cross-study comparison RECORLEV ALT >3X ULN (includes those > 5x ULN) 10.6% ALT >5x ULN 3.2% Total bilirubin values > 1.5x ULN 0% Liver warning & precautions To be determined Monitoring SONICS Monitoring Protocol At least once every two weeks during dose titration. Monitored monthly for

  16. Slide 16: LOGICS: a Phase 3 randomized withdrawal trial

    Slide 16: LOGICS: a Phase 3 randomized withdrawal trial

    LOGICS: a phase withdrawal trial 3 placebo-controlled randomized ~ 8 weeks** Range of 14 to 19 weeks ~8 weeks Randomized Withdrawal (Active) Restoration Phase levoketoconazole Titration-Maintenance: open-label levoketoconazole* Randomized Withdrawal (Placebo) Enrollment Primary endpoint Design Study

  17. Slide 17: LOGICS study sample size and power

    Slide 17: LOGICS study sample size and power

    LOGICS study sample size and power Randomized Withdrawal (Active) Active % who lose response With at least 42 informative completers* of the primary endpoint, if A is less than B by 35% or more an inference of statistical significant difference is highly likely A Placebo % who lose response Randomiz

  18. Slide 18: Recorlev status and next steps

    Slide 18: Recorlev status and next steps

    Recorlev status and next steps LOGICS Top-line results anticipated at the end of Q2 or during Q3 2020 Labeling Certain parts of the Recorlev label concerning safety (e.g. toxicology) will derive from the current ketoconazole tablets label, potentially supplemented by newer information in the public

  19. Slide 19: Recorlev Market Assessment

    Slide 19: Recorlev Market Assessment

    RECORLEV MARKET ASSESSMENT 19 The safety and efficacy of Recorlev (levoketoconazole) for treatment of endogenous Cushing's syndrome has not been established.

  20. Slide 20: Cushing's syndrome market assessment and key findings

    Slide 20: Cushing's syndrome market assessment and key findings

    Cushing’s syndrome (CS) market findings assessment and key Strongbridge CS Market Assessment Key Findings + Landscape Assessment Primary Research MARKET LANDSCAPE of ~ 8,000 patients Secondary Research - Informed the market overview and competitive assessment Qualitative HCP Research − − − 13 Endocr

  21. Slide 21: Market landscape: U.S. CS prevalence and pharmacotherapy

    Slide 21: Market landscape: U.S. CS prevalence and pharmacotherapy

    MARKET LANDSCAPE U.S. Cushing’s syndrome prevalence and pharmacotherapy landscape Patients ~25,000 Diagnosed ~21,500 Non-malignant diagnosed receive surgery as first-line treatment ~20,600 >80% Adult non-malignant diagnosed ~8,000 Rx treated adult non-malignant pharmaceutical treatment rate ~40% ~3,

  22. Slide 22: Market landscape: current CS product market shares

    Slide 22: Market landscape: current CS product market shares

    MARKET LANDSCAPE Approved Products 6% Signifor 7% Signifor LAR Current Cushing’s syndrome product market shares 19% metyrapone 14% Korlym Current CS Market Share of Prevalence of Endogenous Cushing’s syndrome in US 12% mitotane ~8,000 Rx treated adult non-malignant patients ~25,000 16% cabergoline 8

  23. Slide 23: Unmet need exists

    Slide 23: Unmet need exists

    UNMET NEED EXISTS Endocrinologists Reported Product Satisfaction Level interest in new treatment options Endocrinologists Express a High Level of Interest in New Treatments % Reporting Satisfaction Level 7-9** Not at all interested 1 | 9 | Extremely interested 36% 18% 27% of endocrinologists have mo

  24. Slide 24: Potentially competitive profile: endocrinologist reaction

    Slide 24: Potentially competitive profile: endocrinologist reaction

    POTENTIALLY COMPETITIVE PROFILE Endocrinologists reaction to the product profile Recorlev target Endocrinologists % rating 6 or higher Reporting 73% 86% Likelihood to Prescribe Endocrinologists claiming to have > 40 CS patients seen in last 6 months** 70% 81% Fills an Unmet Need Overall Endocrinolog

  25. Slide 25: Recorlev and ketoconazole product profiles

    Slide 25: Recorlev and ketoconazole product profiles

    POTENTIALLY COMPETITIVE PROFILE profiles* KETOCONAZOLE Recorlev and ketoconazole product RECORLEV Indication Anticipated labeling for the treatment of CS Indicated as a last line anti-fungal; FDA label warns that the use of ketoconazole in Cushing’s syndrome has not been approved Liver Safety In SON

  26. Slide 26: Payer access: current branded CS therapy pricing

    Slide 26: Payer access: current branded CS therapy pricing

    PAYER ACCESS Current branded Cushing’s syndrome therapy pricing US$ ~165K US$ ~755K Annual Wholesale\ Acquisition Cost SIGNIFOR/SIGNIFOR LAR KORLYM ~$165k ~$189k – ~$755k* Current analogues in CS category Source: Red Book, Signifor Prescribing Info, Signifor LAR Prescribing Info, Korlym Prescribing

  27. Slide 27: Payer access: branded CS products' coverage

    Slide 27: Payer access: branded CS products' coverage

    PAYER ACCESS Branded CS products’ KORLYM Prior Authorization coverage SIGNIFOR Prior Authorization Plan Coverage Step Edit* Coverage Step Edit* Aetna Specialty Specialty CVS Caremark Non-preferred Non-preferred Express Scripts Non-preferred Preferred** Humana Non-preferred Info not available Non-pre

  28. Slide 28: Summary results of Recorlev payer research

    Slide 28: Summary results of Recorlev payer research

    PAYER ACCESS Summary results of Recorlev payer research Payers viewed Recorlev Sonics’ clinical efficacy and safety benefits profile favorably How interested would you be to cover/include on formulary? Payers expressed initial willingness to provide coverage throughout a tested price range of $200K

  29. Slide 29: Next generation products expected to lead the market

    Slide 29: Next generation products expected to lead the market

    Next generation products are expected to lead the market in the future Current Approved Products Unapproved Products Future Next Generation Approved Products– Current And Unapproved Products Potential Next Generation Products: Recorlev, osilodrostat, relacorilant* Source: Company sponsored research

  30. Slide 30: Leverage existing infrastructure to commercialize Recorlev

    Slide 30: Leverage existing infrastructure to commercialize Recorlev

    Upon approval, fully leverage existing Strongbridge infrastructure and rare disease experience to commercialize Recorlev AWARENESS & EDUCATION MARKETING & ANALYTICS ACCESS & PATIENT SUPPORT FIELD FORCE • Engage top payers to create additional choices for endocrinologists • Prioritize target customer

  31. Slide 31: CS stakeholder targeting approach

    Slide 31: CS stakeholder targeting approach

    Cushing’s syndrome stakeholder targeting approach Medical Claims Data RX Data ~8,000 Endocrinologists ~1,500-2,000 Community and Neuroendocrine Specialists ~125-150 Pituitary Centers and KOLs Preliminary plans ~25-45 Customer Facing* Positions at Launch 31 The safety and efficacy of Recorlev (levoke

  32. Slide 32: KEVEYIS (dichlorphenamide)

    Slide 32: KEVEYIS (dichlorphenamide)

    (dichlorphenamide) * FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis 32 KEVEYIS The first and only FDA-approved therapy for primary periodic paralysis*

  33. Slide 33: Primary periodic paralysis: a spectrum of rare disorders

    Slide 33: Primary periodic paralysis: a spectrum of rare disorders

    Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders PPP Symptoms/Triggers Impact of Attacks Frequency Causes recurrent, progressive, and debilitating episodes of muscle weakness and temporary paralysis2-4 Paralytic attacks are acute episodes that can be debilita

  34. Slide 34: Keveyis approved for the treatment of PPP in the US

    Slide 34: Keveyis approved for the treatment of PPP in the US

    Keveyis approved for the treatment of PPP in the US The first and only Dosing in an oral ~4,000 – 5,000* FDA-approved therapy indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants tablet Starting dose is formulation Can be titrated up to 100 mg 2

  35. Slide 35: Treatment with Keveyis decreased weekly attack rates

    Slide 35: Treatment with Keveyis decreased weekly attack rates

    Treatment with Keveyis decreased weekly attack rates Decreased weekly attack rates from baseline to Mean decrease in attack rates relative to placebo Study 1 Study 2 week 9 Hypokalemic Hyperkalemic -3.9 4.8 4.0 p=0.10* -2.3 attacks per week -2.2 2.4 2.0 p=0.02* 1.8 1.1 p=0.006 0.9 0.3 Mean weekly at

  36. Slide 36: Our commitment to primary periodic paralysis

    Slide 36: Our commitment to primary periodic paralysis

    Our commitment to primary periodic paralysis Suite of Patient Services Personalized Support Community Connection Access Assistance Education & Public Awareness Genetic Testing 29-MEMBER CUSTOMER FACING* TEAM DEPLOYED 36 *Customer facing positions may include sales, access managers, and MSLs

  37. Slide 37: Strategic priorities & revenue guidance

    Slide 37: Strategic priorities & revenue guidance

    Strategic priorities & revenue guidance Continue to Drive Revenue Growth and increase positive contribution margin Pursue Life Cycle 2020 Revenue guidance of $26-$27 Million Building off 2019 revenue of $21.7 Million Opportunities extend exclusivity runway beyond 2022 14 US patent applications filed

  38. Slide 38: IP & Financials

    Slide 38: IP & Financials

    IP & FINANCIALS —ESETllUlUlU

  39. Slide 39: Intellectual property and orphan exclusivity

    Slide 39: Intellectual property and orphan exclusivity

    Intellectual property and orphan exclusivity Intellectual Property Orphan Exclusivity EU US EU US Method of use: treating Cushing’s syndrome Method of use: treating Cushing’s syndrome 10 years 7 years RECORLEV 2026 2026 Filed patent application for modified release formulation 10 years 7 years Modif

  40. Slide 40: Summary financial information

    Slide 40: Summary financial information

    Summary financial information* ~$78M in cash, cash equivalents, and marketable securities no debt ~54.2M shares outstanding Cash runway through 2019 revenue of $21.7 million for Keveyis 29% growth from 2018 2020 full-year Keveyis revenue guidance of $26—$27 million 3Q 2021 * As of 12/31/2019 40

  41. Slide 41: 2020 key priorities

    Slide 41: 2020 key priorities

    2020 key priorities 2020 Key Priorities Report top-line results for the Phase 3 LOGICS study of RECORLEV™ in endogenous Cushing’s syndrome at the end of Q2 or during Q3 2020 Submit a NDA for Recorlev to the U.S. FDA approximately 6 months after reporting top-line LOGICS results Execute on life cycle

  42. Slide 42: Strongbridge Biopharma plc

    Slide 42: Strongbridge Biopharma plc

    BIOPHARMA PLC 42 STRONGBRIDGE

Source: SEC EDGAR · 8-K filed Feb 25, 2020

More decks from Strongbridge Biopharma plc